Discovery of a novel 2-(1H-pyrazolo[3,4-b]pyridin-1-yl)thiazole derivative as an EPreceptor antagonist and in vivo studies in a bone fracture model.

Abstract

We describe a medicinal chemistry approach to the discovery of a novel EPantagonist exhibiting high potency and good pharmacokinetics. Our starting point is 1, an EPreceptor antagonist that exhibits pharmacological efficacy in cystometry models following intravenous administration. Despite its good potency in vitro, the high lipophilicity of 1 is a concern in long-term in vivo studies. Further medicinal chemistry efforts identified 4 as an improved lead compound with good in vitro ADME profile applicable to long term in vivo studies. A rat fracture study was conducted with 4 for 4 weeks to validate its utility in bone fracture healing. The results suggest that this EPreceptor antagonist stimulates callus formation and thus 4 has potential for enhancing fracture healing.